A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.

Inclusion Criteria: * History of episodic or chronic migraine with or without aura meeting the diagnostic criteria listed in ICHD-III (International Classification of Headache Disorders) beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction). * Capable of cooperating with the study protocol and to sign an informed consent. Exclusion Criteria: * Patients having received Botox treatment in the head region in the prior 4 months. * Patients having received supraorbital or occipital nerve blocks in the prior 4 months. * History of Medication Overuse Headache. * Patients using opioid medication. * Allodynia: intolerance to supraorbital and/or occipital neurostimulation (allodynia) that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 3 minutes of neurostimulation). * Implanted metal or electrical devices in the head (not including dental implants). * Patient having had a previous experience with the Relievion™ device. * Patients who have concomitant epilepsy. * History of neurosurgical interventions. * Patients with implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps. * History of drug abuse or alcoholism. * Participation in current clinical study or participated in a clinical study within 3 months prior to this study. * Skin lesion or inflammation at the region of the stimulating electrodes. * Personality or somatoform disorder. * Pregnancy or Lactation. * Women of reproductive age not using efficient contraceptive method. * History of cerebrovascular event. * Subjects with recent brain or facial trauma (occurred less than 3 months prior to this study).